In diabetic kidney disease models, SGLT2 inhibitors like dapagliflozin and empagliflozin have shown significant anti-inflammatory, anti-oxidative, and anti-fibrotic properties. The gene discussed is SLC5A2; the disease is diabetic kidney disease.